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Any reflection on history, even as recent 
as the past 20 years, invites a humble 
re-evaluation of the myth of human 
progress. In public health, progress has 
been made; certainly the number of 
children who die each year has declined 
progressively. However, rereading the 
work of scientists who investigated the 
major cause of death in childhood, acute 
respiratory tract infection (ARI), in the 
1980s evokes an uncanny resonance 
with present-day concerns.
At that time, the attention of the 
global public health community was on 
oral rehydration therapy, universal im-
munization, promotion of breastfeed-
ing and the use of growth monitoring 
charts.2 Lower respiratory tract infec-
tions (LRTIs) attracted relatively little 
attention. With considerable perspicac-
ity, the Board of Science and Technol-
ogy for International Development 
(BOSTID) at the National Academy of 
Sciences, United States of America, de-
fined ARI as one of six priority areas for 
research funding in 1983 and convened 
an international ARI meeting. The par-
ticipants identified three prerequisites 
for relevant research:
Studies should be undertaken in a 1. 
wide variety of countries to give full 
geographical representation to the 
children of the developing world and 
they should be standardized to facili-
tate international comparisons.
The etiology of ARI should be in-2. 
vestigated first because it would be 
essential for later research on preven-
tion and case management.
The international research group 3. 
should be coordinated by a centre 
that could provide technical assis-
tance and quality control, and could 
foster active collaboration between 
investigators.3
Over the next 5 years, BOSTID under-
took such a project, involving investiga-
tors from 12 sites who met on an annual 
basis to agree on clinical definitions, 
laboratory methods, study designs and 
analysis plans. The results of the pro-
gramme were published in 1990 in a 
supplement of the Reviews of Infectious 
Diseases. The supplement illustrates the 
wide diversity of research activities in 
the programme from community-based 
epidemiology to laboratory com-
parisons of antigen detection methods, 
evaluations of recent antibiotic exposure 
and pathological studies of postmortem 
specimens. The anchor of the supple-
ment is the paper “The epidemiology of 
acute respiratory tract infection in young 
children: comparison of findings from 
several developing countries” by Beatrice 
Selwyn on behalf of the BOSTID inves-
tigator group, reporting a standardized 
analysis of the epidemiology of ARI in 
young children from 10 sites.1
It is a paper of truly astonishing 
ambition, combining 16 studies of up-
per and lower respiratory tract infec-
tions in both community- and hospital- 
based settings. It examines incidence, 
prevalence, duration, case-fatality and 
the effects of age, sex and season on the 
patterns of disease. It describes bacte-
rial and viral etiology and interrogates 
the clinical signs of respiratory tract 
infections to define these diseases more 
accurately. It evaluates risk factors for 
respiratory tract infections across sev-
eral sites, including mother’s age and 
education, weight-for-age percentiles, 
and crowding and smoking in the 
household. The hospital-based studies 
alone reported nearly 4000 episodes of 
ARI and the eight community-based 
cohort studies each included reports of 
between 8000 to 93 000 home visits.
The key findings of the analysis 
were:
The incidence of LRTIs varied forty-1. 
fold across the sites but the incidence 
of all respiratory tract infections (up-
per and lower combined) was re-
markably consistent.
The incidence and case-fatality of 2. 
LRTIs were consistently higher 
among younger children aged < 18 
months.
The prevalence of ARI symptoms, at 3. 
any one time, was 22–40%.
Viruses caused more episodes of ARI 4. 
than did bacteria.
Respiratory syncytial virus was the 
commonest viral cause of LRTIs and 
Streptococcus pneumoniae (pneumo-
coccus) and Haemophilus influen-
zae were the commonest bacterial 
causes. A significant fraction (one-third 
in one hospital) of all H. influenzae 
infections were nontypeable.
Not all of the insights of the 
BOSTID research group could be sum-
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marized in a single paper or even a 
supplement. The programme provided 
an intellectual forum in which many 
lines of enquiry were distilled.2 The 
complete lack of understanding of how 
or why children die from pneumonia 
was identified as a critical future re-
search question. The pathogenesis of 
ARI, including the complex synergism 
between viral and bacterial pathogens, 
was a second significant area. The in-
vestigators believed that understanding 
the mechanisms that controlled the 
magnitude and selectivity of the hu-
man inflammatory response would of-
fer practical opportunities to influence 
disease outcome. This insight would 
need to be augmented by knowledge 
of the modulating effects of nutritional 
status and immune deficiency. The role 
of access to health care, and the quality 
of that care, in the outcome of disease 
was a third significant area of research 
that was likely to be fruitful.2 The list is 
strikingly similar to an evaluation of the 
research required to tackle pneumonia 
today.4 With the exception of oxygen 
therapy for severe pneumonia and zinc 
supplementation to prevent disease, 
there has been little clinical amelioration 
of pneumonia through developments in 
clinical science in 20 years.
The reasons for this apparent neglect 
probably lie with subsequent advances 
in public health policy and vaccine 
development. In 1991, WHO formu-
lated its case-management strategy for 
pneumonia. The strategy was driven by 
bacteriological studies, particularly those 
incorporating lung aspirates, which iden-
tified pneumococcus and H. influenzae 
type b (Hib) as the dominant causes 
of severe and fatal pneumonia. These 
infections were treatable with cheap and 
widely available antibiotics. The policy 
was designed to identify patients with the 
syndrome of pneumonia at an early stage, 
often without a doctor’s examination, and 
to initiate treatment with life-saving an-
tibiotics. Studies undertaken around this 
time indicated that the case-management 
approach was capable of reducing all-
cause mortality in children aged < 5 years 
by 20–24%.5 Access to antibiotics has 
improved generally over the past 15 years 
but the fact that two million children 
still die of pneumonia each year suggests 
that the potential of this policy was never 
fully realized.
Focus on case management was 
followed, in the second half of the 
1990s, by enthusiasm for new vaccines. 
A protein-conjugated Hib vaccine was 
shown to prevent approximately 20% 
of radiologically confirmed pneumonia 
in a trial in children in the Gambia. This 
seeded the idea that Hib vaccine, and 
possibly the pneumococcal conjugate 
vaccines that were in development at 
that time, could be deployed in low-
income countries to prevent a signifi-
cant fraction of the burden of child-
hood pneumonia. The taxing questions 
were how to finance and distribute 
these relatively expensive products in 
countries with inadequate resources.
The task was taken up by the GAVI 
Alliance (formerly known as the Global 
Alliance of Vaccines and Immuniza-
tion), which has funded Hib vaccine 
introduction since 2001 and will begin 
supporting the introduction of the 
pneumococcal vaccine in a few develop-
ing countries in 2008. Experience with 
Hib vaccine suggests that the introduc-
tion process is slow but the fact that it 
has started challenges us to consider the 
management of a spectrum of pneu-
monia pathogens that may no longer 
be dominated by the easy targets of 
pneumococcus and Hib.6
Over this period the epidemiology 
and etiology of pneumonia have also 
evolved, particularly as a consequence 
of HIV. Unusual pathogens such as 
Pneumocystis jiroveci and cytomega-
lovirus have a prominent place in the 
etiology of pneumonia among children 
with HIV. Mycobacterium tuberculosis is 
a common cause of presentation with 
pneumonia in areas of high HIV preva-
lence regardless of HIV status.7 With 
advances in molecular diagnostic tools, 
we have also identified novel pathogens, 
such as human metapneumovirus and 
new human coronaviruses, in immu-
nocompetent children with respiratory 
disease.
The process initiated by the 
BOSTID studies has therefore devel-
oped a new relevance two decades later: 
interest in pneumonia research is cur-
rently being rekindled by both scientists 
and funders.8 In her introduction to 
the BOSTID supplement, Judith Bale 
reflects: “With all the complexities of 
ARI, it is unrealistic to search for a 
‘magic bullet’. Research must include 
a focus on basic understanding of ARI, 
particularly the factors leading to severe 
disease.” Given the complexities of the 
problem, a comprehensive and accurate 
description of the epidemiology and 
etiology will once again become the 
foundation of pneumonia research. As 
we rebuild a global network of pneu-
monia research sites, we might ponder 
how we failed to sustain the investment 
of the BOSTID initiative. Childhood 
pneumonia has remained the dominant 
public health problem in the developing 
world but we have not cultivated local 
research capacity in pneumonia.
What can be gleaned from the 
BOSTID studies to optimize a new 
pneumonia research network? The 
paper by Selwyn et al.1 was prescient, 
courageous and comprehensive but it 
also revealed some of the difficulties in 
creating an integrated global description 
of respiratory tract infections. The inclu-
sion of upper respiratory tract infection 
(URTI) affirmed its biological connec-
tion with LRTI but also undermined 
the public health impact of the studies, 
given the generally benign perception 
of URTI. Site selection gave prefer-
ence to underprivileged populations 
but, because the sites had to be close to 
competent laboratories (which are rare 
in low-income countries), the repre-
sentation of the developing world was 
uneven. For example, five out of the 12 
sites were located in Central and South 
America. A standardized case-definition 
is essential for international comparisons 
but most of the BOSTID investigators 
amended the standardized definitions, 
thus producing, in some cases, excep-
tional incidence results. The failure to 
obtain lung aspirate material reduced 
the sensitivity of the study to bacterial 
causes of pneumonia.
These factors do not detract from 
what was a Herculean task performed 
in an era when global networks were 
uncommon and international commu-
nications were challenging. However, 
the scientific community of today needs 
to regenerate pneumonia research in 
developing countries and the first step 
will be to learn from the difficulties 
encountered by this pioneering pro-
gramme. As we take up the task, we are 
indebted to the BOSTID group for this 
far-sighted publication.  ■
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